CEO Executive AssistantClinical operations is one of the most execution-intensive domains in any biotech company. Running clinical trials requires meticulous project management, regulatory compliance, site coordination, data management, and patient safety monitoring, all on tight timelines with high regulatory and scientific stakes. It is also an area where biotech CEOs are frequently tempted to over-involve themselves, especially when programs are in critical phases and investor timelines are tight.
The following checklist helps biotech CEOs assess their current clinical operations delegation, identify gaps, and implement a more effective structure. Each checklist item represents either a delegation action to take or a system to establish that reduces the CEO’s operational burden while maintaining appropriate oversight.
Leadership and Accountability Checklist
Appoint a Chief Medical Officer or VP of Clinical Development as primary clinical delegate. The CEO should not be the operational owner of clinical programs. A qualified CMO or VP of Clinical Development should have clear authority over trial design, protocol decisions, site management, data review, and clinical team leadership. If this role is vacant or understaffed, delegation of clinical operations cannot work effectively.
Document the CMO’s decision authority in writing. What can the CMO decide independently? What requires CEO notification? What requires CEO approval? Examples of typical CMO-level authority: approving protocol amendments below a defined complexity threshold, selecting CROs within an approved budget range, making site activation decisions, and managing clinical staff. Document these explicitly.
Ensure the CMO has direct access to the board’s scientific or clinical committee. Clinical operations oversight at the board level should flow through the CMO, not exclusively through the CEO. The CEO facilitates this relationship but does not serve as the sole conduit.
Define the CEO’s role in clinical program meetings. The CEO should attend program steering committee meetings for the company’s lead program on a quarterly basis, not monthly, and should attend as a strategic participant, not as a clinical operations reviewer. The CMO chairs these meetings.
Clinical Trial Execution Checklist
Delegate CRO relationship management to the CMO and Clinical Operations team. Day-to-day CRO interactions, including project management calls, milestone tracking, and issue resolution, should be managed by the clinical operations team, not the CEO. The CEO’s CRO engagement should be limited to quarterly strategic reviews and significant contractual decisions.
Establish a site activation dashboard that the CEO reviews, not manages. Site activation timelines are a critical operational metric for clinical trials. The CEO should receive a weekly summary of site activation status (how many sites are active, how many in startup, any sites at risk of delay) without being the person who manages site activation directly.
Delegate patient enrollment monitoring to clinical operations. Enrollment tracking is an operational function. The CEO should see enrollment trend data in structured reporting but should not be calling sites, adjusting enrollment strategies, or managing the enrollment challenge personally.
Confirm the data safety monitoring board (DSMB) structure is independent and properly resourced. The DSMB provides external safety oversight of clinical trials. The CEO’s role is to ensure this structure exists and is appropriately independent, not to participate in DSMB deliberations or review safety data outside of defined reporting channels.
Safety and Regulatory Compliance Checklist
Delegate pharmacovigilance reporting to Medical Affairs or Safety function. Adverse event reporting, including serious adverse event (SAE) narratives and expedited safety reports, should be managed by a qualified pharmacovigilance team. The CEO should receive a summary of significant safety events but should not be involved in the reporting process itself.
Confirm the clinical quality management system is owned by Quality, not the CEO. Clinical quality, including SOPs, training documentation, audit readiness, and deviation management, should be owned by a Quality Director or VP of Quality reporting through the CMO or COO structure. This is a specialized compliance function that requires dedicated expertise.
Establish clear escalation protocols for significant safety findings. Define the specific circumstances under which the CMO escalates a safety finding to the CEO: a new serious adverse event that could affect the program’s risk-benefit profile, a safety finding that requires FDA notification, or a safety signal that may require a clinical hold. Outside of these triggers, safety management is the CMO’s domain.
For a comprehensive framework on how clinical operations delegation connects to regulatory affairs oversight, see pharma regulatory affairs, which covers how biotech and pharma CEOs can structure delegation across the regulatory function that governs clinical program submissions.
Reporting and Oversight Checklist
Implement a weekly clinical operations update from the CMO. This should be a brief written summary: key milestones achieved, enrollment status, any significant issues and the CMO’s plan to address them, and any decisions the CEO needs to make or be aware of. Total reading time should not exceed 10 minutes.
Establish a monthly clinical program review. A structured review covering each active clinical program’s status against its milestones. The CMO presents; the CEO asks strategic questions. This meeting should be 60 to 90 minutes maximum.
Create a clinical milestone achievement tracker that ties to investor milestones. Clinical milestones are investor-facing commitments for most biotech companies. Ensure the internal tracking system mirrors the publicly disclosed milestone language and that the CMO produces a quarterly milestone status report that can be used directly in investor communications.
Confirm that data readout planning is owned by the CMO and statistical team. Data readout strategy, including timing, statistical analysis plan, and publication strategy, should be managed by the CMO and biostatistics team in partnership with the CSO. The CEO reviews and approves the strategic framing; the CMO and team own the technical execution.
Budget and Resource Checklist
Delegate clinical trial budget management to CMO and Finance. Clinical trial budgets are managed by the CMO in partnership with the finance function. The CEO approves the annual clinical budget and significant modifications above a defined threshold. Within-budget management decisions belong to the CMO.
Confirm CRO contract terms are negotiated by the Clinical Operations team with legal support. CRO contracts involve complex operational terms that clinical operations specialists understand better than the CEO. The CEO should review and approve the final commercial terms of significant CRO agreements but should not be involved in the detailed contract negotiation.
Establish a monthly burn rate review for clinical programs. Clinical development is expensive, and understanding the rate of capital deployment against the clinical plan is important for biotech CEO oversight. A monthly burn rate summary produced by Finance with CMO annotation is sufficient for this oversight without requiring CEO involvement in clinical spending decisions.
According to Forbes analysis of biotech governance practices, biotech CEOs who build effective delegation structures for clinical operations free themselves for the investor, partnership, and strategic work that drives company value. The clinical machine runs better when it is led by clinical experts with clear authority.
Communication and Investor Relations Checklist
Develop a clinical narrative for investor use that the CEO owns but the CMO informs. Investor communications about clinical programs should be the CEO’s responsibility in terms of delivery and ownership, but the clinical content should be reviewed and validated by the CMO before use. Establish a protocol for clinical content review before any investor communication that includes program-specific clinical data.
Confirm the CEO’s role in FDA interactions is strategic, not operational. FDA meetings, particularly Type B meetings and pre-NDA meetings, benefit from CEO presence to signal organizational commitment. But the clinical and regulatory content of these meetings should be prepared and presented by the CMO and regulatory affairs team. The CEO should be briefed before these meetings and follow up on action items; they should not be preparing the content.
See pharma CEO clinical ops for a detailed framework on how pharma and biotech CEOs can structure their engagement with the FDA and other regulatory bodies through appropriate delegation of clinical and regulatory expertise.
Using This Checklist
Work through this checklist with your CMO and CFO. For each item where the current state does not match the described delegation, create a specific action item with a responsible owner and a timeline. The checklist is not a one-time assessment but an ongoing governance tool. Review it quarterly as programs advance and as the organization grows.
The biotech CEO who builds effective clinical operations delegation creates an organization where excellent clinical science is managed by expert clinicians with appropriate executive oversight, where the CEO is informed and accountable without being operationally enmeshed, and where the entire organization can move faster because clinical decisions are made at the right level.
Related Reading
For further context, explore Delegation Checklist for Energy CEO: Capital Projects and Delegation Checklist for Energy CEO: Regulatory Compliance.